This study’s findings will help congenital neurological disease (e.g. spinal muscular atrophy) specialists better understand the mechanisms and components involved in CNS development. Notably, the findings of this work demonstrate unequivocally that Ddx20 is a novel Olig2-interacting factor and a potent suppressor of the p53 pathway, contributing to the maintenance of neuronal and oligodendrocyte progenitor cells during CNS development. Therefore, Ddx20 and Olig2 are promising molecular targets for development of future therapeutic strategies.
The central nervous system, which comprises the brain and spinal cord, is constructed by the proper proliferation of neural progenitor cells and their differentiation into neurons and glial cells. The transcription factor Olig2 is expressed in neural progenitor cells and is essential for the development of motor neurons and oligodendrocytes, and also contributes to the proliferation of neural progenitor cells. However, it has remained unclear how Olig2 regulates these diverse biological processes. Therefore, this research group searched for a novel Olig2 binding factors and aimed to elucidate the developmental mechanisms involved in these factors and Olig2.
In a ground-breaking recent study, a team of scientists based at Niigata University, identified a novel Olig2 binding protein called Ddx20 (also known as Gemin3 or DP103) that interacts with Olig2 during neural development. Ddx20 is known as a multifunctional molecule that regulates transcription, RNA splicing, and protein translation. Furthermore, Ddx20 interacts with SMN, a causative gene of spinal muscular atrophy (SMA), and is deeply involved in the pathogenesis of SMA. In this study, the scientists generated Ddx20 conditional knockout mice to investigate the function of Ddx20 during CNS development. They found that apoptosis occurs rapidly in neural progenitor cells and oligodendrocyte progenitor cells. The mechanism responsible for the cell death was investigated, and excessive nuclear accumulation of p53, a tumor suppressor gene product, was found. Interestingly, in Ddx20-deficient mice, the SMN protein was destabilized and the RNA splicing mechanisms were abnormal, leading to splicing dysregulation of Mdm2, a p53 inhibitor. They proceeded to further understand the mechanism by which Olig2 contributes to neural progenitor cell proliferation and survival. In these experiments, the authors found that Ddx20 levels were lower in Olig2 deficient mice than in wild type mice. Moreover, the SMN protein levels were lower in Olig2-deficient mice than in wild type mice. In addition, some spliceosomal RNA and Mdm2 splicing were dysregulated in Olig2-deficient mice than in wild type mice. Lastly, the p53 was more activated in Olig2-deficient mice than in wild type mice.
In summary, the discovery reported in this study show that Olig2 maintains the Ddx20-SMN complex involved in the regulation of Mdm2 splicing, which in turn suppress p53 activation. In an interview with Professor Hirohide Takebayashi, who led this research at Niigata University, said, “This study highlights that a transcriptional factor, Olig2, affects not only transcriptional regulation but also RNA metabolism through Ddx20 stabilization, revealing the diverse functions of Olig2. Importantly, since Olig2 has been reported to be involved not only in neural development but also in the progression of glioma and melanoma. On the other hand, Ddx20 has also been known as an initiator of various cancers. Therefore, the interaction of these two factors may play a key role in the development and progression of the cancers. We believe that further research might provide clues to elucidate the etiology of congenital neurological diseases and cancers, including the development of therapeutic strategies against them.”
View original article here Source